Human FGFR4 _CD334 Protein Vector: HEK293
- Known as:
- Human FGFR4 _CD334 Protein Vector: HEK293
- Catalog number:
- 10109-H01H
- Product Quantity:
- 200μg
- Category:
- -
- Supplier:
- Provo
- Gene target:
- Human FGFR4 _CD334 Protein Vector: HEK293
Related genes to: Human FGFR4 _CD334 Protein Vector: HEK293
- Gene:
- FGFR4 NIH gene
- Name:
- fibroblast growth factor receptor 4
- Previous symbol:
- -
- Synonyms:
- JTK2, CD334
- Chromosome:
- 5q35.2
- Locus Type:
- gene with protein product
- Date approved:
- 1991-07-25
- Date modifiied:
- 2015-08-25
Related products to: Human FGFR4 _CD334 Protein Vector: HEK293
Related articles to: Human FGFR4 _CD334 Protein Vector: HEK293
- Endocrine therapy resistance is the major challenge of managing patients with estrogen receptor positive (ER+) breast cancer. We previously reported frequent overexpression of FGFR4 in endocrine-resistant cell lines and breast cancers that recurred and metastasized following endocrine therapy, suggesting FGFR4 as a potential driver of endocrine resistance. In this study, we investigated the role of FGFR4 in mediating endocrine resistance and explored the therapeutic potential of targeting FGFR4 in advanced breast cancer. - Source: PubMed
Publication date: 2025/03/17
Ding KaiChen LyuqinLevine Kevin MSikora Matthew JTasdemir NilgunDabbs DavidJankowitz RachelHazan RachelShah OsamaAtkinson JennyLee Adrian VOesterreich Steffi - Triple-negative breast cancer (TNBC) is characterized by high malignancy, strong invasiveness, and a propensity for distant metastasis, leading to poor prognosis and relatively limited treatment options. Metformin, as a first-line oral hypoglycemic agent, has garnered widespread research interest in recent years due to its potential in cancer prevention and treatment. However, its efficacy varies significantly across different tumor types. Histone deacetylase inhibitors (HDACi), such as SAHA, have demonstrated antitumor activity, but TNBC responds poorly to HDACi monotherapy, possibly due to feedback activation of the JAK-STAT pathway. Exploring the synergistic potential and underlying mechanisms of combining metformin with HDACi in TNBC treatment is crucial. - Source: PubMed
Publication date: 2025/03/17
Gu ZhangyuanYe FuguiLuo HongLi XiaoguangGong YueMao ShiqiJia XiaoqingHan XiangchenHan BoyueFu YunCheng XiaolinLi JiejingShao ZhimingWen PeizhenHu XinZhuang Zhigang - Colorectal cancer (CRC) is the second most common cancer in men and third in females, a heterogeneous disease involving multistep mechanisms that represents 10% of all cancers globally. This study investigates gene mutation profiling in CRC using Next-Generation sequencing machine. - Source: PubMed
Publication date: 2025/03/06
Afolabi Hafeez AbiolaSalleh Salzihan MdZakaria ZaidiSeng Ch'ng EweNafi Siti Norasikin MohdAziz Ahmad Aizat Bin AbdulZainon Wan Mohd Nazri WanIrekola Ahmad AdebayoWada YusufAl-Mhanna Sameer BadriElesho Rashidat Folashade - ER-positive/HER2-negative (ERpHER2n) breast cancer classified as PAM50 HER2-enriched (ERpHER2n-HER2E) represents a small high-risk patient subgroup. In this study, we investigate genomic, transcriptomic, and clinical features of ERpHER2n-HER2E breast tumors using two primary ERpHER2n cohorts comprising a total of 5640 patients. We show that ERpHER2n-HER2E tumors exhibit aggressive clinical features and poorer clinical outcomes compared to Luminal A and Luminal B tumors. Furthermore, ERpHER2n-HER2E breast cancer does not consist of misclassified or HER2-low cases, has little impact of ERBB2, is highly proliferative and less ER dependent than other luminal subtypes. It is not an obvious biological entity but is nevertheless associated with potentially targetable molecular features, notably a high immune response and high FGFR4 expression. Strikingly, molecular features that define the HER2E subtype in luminal disease are also consistent in HER2-positive disease, including an epigenetic mechanism for high FGFR4 expression in breast cancer. - Source: PubMed
Publication date: 2025/03/05
Hohmann LennartSigurjonsdottir KristinCampos Ana BoschNacer Deborah FVeerla SrinivasRosengren FridaReddy Poojaswini ThimmarayaHäkkinen JariNordborg NicklasVallon-Christersson JohanMemari YasinBlack DaniellaBowden RamsayDavies Helen RBorg ÅkeNik-Zainal SerenaStaaf Johan - Fibroblast growth factor 1-4 (FGFR1-4) are well-known oncogenic drivers in many cancer types. Here, we studied the role of FGFRs in uterine leiomyoma (UL) that is a benign neoplasm arising from the myometrium and the most common tumour in women. Although ULs can be classified to molecular subtypes based on genetic drivers, potential secondary drivers are not well characterised. - Source: PubMed
Publication date: 2025/02/27
Jokinen ViljaTaira AuroraKolterud ÅsaAhlgren IsaPalin KimmoKatainen RikuRäisänen MarittaKaasinen EeviIlves SiniRaitila AnniinaKopp Kallner HelenaSiili EmmaBützow RalfHeikinheimo OskariPasanen AnnukkaKarhu AuliVälimäki NikoAaltonen Lauri A